These results indicate that Slit2N/Robo4 modulates key cellular functions thatcontribute to lymphangiogenesis, and identify this ligand-receptor pair as apotential drug target to inhibit cancer metastasis via the lymphatic system andto treat other lymphatic pathologies characterized by abnormal VEGF-C/VEGFR-3signaling. Here, ROBO4 is linked to cancer.